NBE-Therapeutics engages in the development of “next-generation”, immune-stimulatory antibody drug conjugates (iADCs) with the objective to develop best-in-class ADC product candidates until clinical proof-of-concept in patients.

Products, services, technology

NBE-002, an anti-ROR1 iADC

Cooperation possibilities

Technology and early ADC development candidate partnering for joint development into the clinic.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2012
  • Number of employees in Switzerland
    20-49
Key business